Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

CAMS Oxford Institute researchers introduced an improved version of a novel all-in-one vaccine against coronavirus threats.

Researchers from the Townsend Group from the MRC Translational Immune Discovery Unit & CAMS Oxford Institute have collaborated with the Howarth Lab from the University of Cambridge and the Bjorkman Group from the California Institute of Technology, to develop an improved version of a novel all-in-one vaccine against coronavirus threats. Results from this study have been published in Nature Nanotechnology.

Previous work by the Townsend and Bjorkman groups contributed to the development of a nanoparticle vaccine (Mosaic-8b RBD-mi3), which was able to target multiple different types of SARS-like betacoronaviruses (sarbecoviruses). This vaccine should enter Phase 1 clinical trials early next year. However, the complex nature of this vaccine makes it challenging to manufacture, which could limit large-scale production of the vaccine in the future. In this Nature Nanotechnology study the authors present an updated version of the vaccine that should be simpler to make.

The Mosaic-8 vaccine developed previously featured Receptor Binding Domains (RBDs) from eight different coronaviruses. RBDs are parts of the viral spike protein that are targeted by antibodies, host proteins that are raised by the immune system in response to pathogens. These eight RBDs were ‘glued’ onto a nanocage structure, allowing one vaccine to present the eight different domains and generate an immune response. The Mosaic-8 vaccine was shown to provide protection against a diverse range of sarbecoviruses, not just the eight with RBDs included in the vaccine.

In this study, Professors Howarth, Townsend and Bjorkman, introduce a new version of the Mosaic-8 vaccine, which they named a Quartet Nanocage vaccine. For the new vaccine, the researchers fused RBDs from four different coronaviruses to make one protein molecule, called a Quartet. The Quartet molecules were then ‘glued’ to the same nanocage structure used previously for the Mosaic-8 vaccine. By making two different Quartets and attaching them to the nanocage, researchers could once again manufacture a vaccine that displays RBDs from eight viruses. However, this time, only three different components needed to be prepared (two Quartets and one nanocage) rather than nine as in the Mosaic-8 (eight RBDs and one nanocage), simplifying the vaccine manufacturing process.

The new Quartet Nanocage vaccines were able to produce a level of immune responses and protection against coronaviruses that were similar, if not better, than the Mosaic-8 vaccine. Another advantage of the Quartet Nanocages is the ability to display more RBDs. The Quartet Nanocage design allows four RBDs to be displayed from one site on the nanocage, rather than needing four individual sites as is the case with the Mosaic-8 design.

Rory Hills, PhD Student at the University of Cambridge and the paper's first author, said: ‘We have shown that a relatively simple vaccine can produce a protective response for several coronaviruses. This is an important step towards our goal of creating vaccines for pandemic threats before they are able to infect humans.’

Read the full paper: www.nature.com/articles/s41565-024-01655-9

Similar stories

New insights into cellular pH regulators could inform research into neurological disease and cancer

High-resolution structures of two proteins that regulate acidity inside cells reveal how they interact with ions and membrane lipids, providing new insights into their roles in disease and potential avenues for drug discovery.

Building the world's evidence base to tackle drug-resistant tuberculosis

£10 million international research programme launches across India, Kazakhstan, Mozambique, South Africa and Vietnam.

A New Layer of Control for a Decades-Old Leukemia Drug

How cells respond to the leukemia drug 6-thioguanine still holds surprises: A new study, led jointly by researchers from CeMM and the University of Oxford identifies NUDT5 as an unexpected regulator of drug sensitivity and reveals that its role has nothing to do with its enzymatic activity.

Team ATLAS sets out strategy to investigate cancer avoidance as part of Cancer Grand Challenges

A new position paper from team ATLAS sets out plans to build a cancer antibody atlas to investigate why some people avoid cancer, while others develop disease.

Decades old puzzle solved as scientists uncover cause of inflammatory bowel disease

Scientists have identified the missing link between a long-known genetic signal in inflammatory bowel disease and a damaging immune response that switches off the body’s natural control of inflammation - opening the door to faster diagnosis and targeted treatment.

Oxford Bundibugyo ebolavirus vaccine candidate receives CEPI backing

The Coalition for Epidemic Preparedness Innovations (CEPI) has announced today that it will urgently accelerate the development of three investigational vaccines targeting the Bundibugyo ebolavirus that has caused a rapidly spreading epidemic in the Democratic Republic of the Congo (DRC) and neighbouring Uganda, including one being developed by the Oxford Vaccine Group at the University of Oxford.